Evidence that in healthy young women, a six-cycle treatment with oral contraceptive containing 30 mcg of ethinylestradiol plus 2 mg of chlormadinone acetate reduces fat mass

Uras, R.; Orrù, Marisa; Etzi, Rossella; Peppi, Giangavino; Marotto, Maria Francesca; Pilloni, Monica; Zedda, Pierina; Lello, Stefano; Melis, Gian Benedetto; Paoletti, Anna Maria

doi:10.1016/j.contraception.2008.08.007

Cited by 17 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of this study seem to show that a six-cycle treatment with an oral contraceptive containing CMA-EE is associated with a decrease in fat mass. 28 This is unexpected in light of previous studies of other contraceptives containing different progestin compounds, such as LNG and DRSP, which did not show similar effects on fat mass. 20,30 The effect of CMA-EE in reducing fat mass is important in preventing cardiovascular disease, diabetes, and breast cancer, and is also important for women afraid of gaining weight during hormonal contraception.…”

Section: Body Weightmentioning

confidence: 82%

Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive

Ferrari¹,

Cannoletta²,

Generali

et al. 2010

OAJC

View full text Add to dashboard Cite

Since their introduction in 1959, development of hormonal contraceptives has been ongoing, with the ultimate aim of creating not only an effective and safe contraceptive method, but also a drug able to meet the need for treatment of other conditions, such as acne, seborrhea, and hirsutism, with few or no side effects. With this objective, a new progestin, chlormadinone acetate (CMA), has been developed as a derivative of progesterone for contraception. This new molecule has been introduced in combination with ethinylestradiol (EE) 30 µg as a safe contraceptive with antiandrogenic properties. Many clinical studies have investigated this new oral combination and found it to be safe, with a Pearl Index similar to that of other combined hormonal contraceptives. CMA, because of its antiandrogenic properties, has been also considered effective for resolution of acne, seborrhea, and hirsutism. The data show it to be a safe molecule in terms of glucose and lipid metabolism. No major weight changes have been linked with its use, and it seems to be the only progestin able to reduce fat mass during use. The CMA-EE combination is well tolerated and acceptable to women. Adverse events related to its use are similar to those reported with other third-generation contraceptives. We can conclude that CMA-EE is an effective, safe, and well tolerated antiandrogenic hormonal contraceptive.

show abstract

Section: Body Weightmentioning

confidence: 82%

Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive

Ferrari¹,

Cannoletta²,

Generali

et al. 2010

OAJC

View full text Add to dashboard Cite

show abstract

“…Moreover, these findings should be interpreted with caution since factors such as the type of progestogen used may influence the outcome. For example, antiandrogenic progestogens such as chlormadinone acetate can counteract fluid retention and even lead to a reduction in body fat [28]. Another study reported differences in young women using OCs, including decreased FFM and decreased levels of DHEA and Insulin-like growth factor-1 (IGF-1) after a 10-week RT program [14].…”

Section: Discussionmentioning

confidence: 99%

“…Second, the inclusion requirement for the contraceptive group was the use of combined contraceptives, regardless of their dose or formulation. This is an important limiting factor, since differences have been observed in the type of contraceptive (monophasic vs triphasic) and in the dose/progestin used [6,28]. Therefore, more studies are needed on the topic to confidently provide recommendations for different population groups.…”

Section: Limitationsmentioning

confidence: 99%

Oral Contraceptive Use does not Negatively Affect Body Composition and Strength Adaptations in Trained Women

García

Vargas-Molina

Espinar³

et al. 2019

Int J Sports Med

View full text Add to dashboard Cite

The purpose was to analyze the influence of oral contraceptive use on body composition and strength levels in trained women. Twenty-three resistance-trained women participated in this study (age=27.4±3.4 years; fat mass=28.0±5.0%; BMI=22.9±2.7 kg∙m-2). Subjects performed an 8-week non-linear resistance-training program. Participants were assigned to either a group that consumed oral contraceptives (n=12, OC) or to a group that did not consume (n=11, NOC). Changes in body composition were measured by dual energy X-ray absorptiometry. Strength performance was assessed via the one maximum repetition (1RM) test in the squat and bench press, and muscular power was evaluated using the countermovement jump (CMJ) test. Fat free mass increased significantly in OC but no changes were seen in NOC. There were no changes in fat mass for either OC or NOC. Significant changes were found in bench press 1RM for both OC and NOC; similarly, increases in squat 1RM were reported in OC and NOC. Alternatively, no significant changes were found in CMJ in both OC and NOC. No significant between-group differences were detected in any of the studied variables. The use of oral contraceptives during resistance training did not negatively affect body composition or strength levels in trained women.

show abstract

“…46 In healthy eumenorrheic women, EE30 + CMA was effective in balancing the effects of ethinyl estradiol on fluid retention and in reducing fat mass. 47 In addition, it was demonstrated that EE30 + CMA does not reduce insulin sensitivity, but is capable of improving the lipid profile. 48,49 These metabolic effects of EE30 + CMA are important in women with hyperandrogenic symptoms, especially those with polycystic ovarian syndrome, in whom the gold standard of estroprogestin treatment is a formulation able to both ameliorate the hyperandrogenic state and be devoid of deleterious effects on metabolic status, particularly glucose-insulin metabolism.…”

Section: Oral Contraceptives Containing Chlormadinone Acetatementioning

confidence: 99%

Use of oral contraceptives in the management of acne

Melis¹,

Orrù²,

Marotto³

et al. 2011

OAJC

Self Cite

View full text Add to dashboard Cite

Abstract:The pathogenesis of acne (the most common disorder involving the sebaceous gland) originates from increased sebum production by the sebaceous gland followed by colonization of the hair follicle with Propionibacterium acnes, hyperkeratinization of the upper follicle, and release of inflammatory mediators into the skin. Androgens are the main stimulators of sebum production. Androgens originate from the gonads and adrenal glands, but can also be locally produced within the sebaceous gland from dehydroepiandrosterone sulfate. In the presence of high androgen levels, which can be either a normal pattern of adolescence or a consequence of gonadal or adrenal disease, overproduction of sebum triggers the pathogenesis of acne which, mainly in adolescent women, has deleterious psychological consequences. Estrogens exert the opposite action on sebum production, probably due to the reduction of androgen availability, a direct consequence of estrogen-related increased production of hepatic sex hormone-binding globulin (SHBG). The inhibition of the hypothalamus-pituitary axis induced by oral contraceptives is followed by reduced androgen production. Oral contraceptives containing ethinyl estradiol, which has strong estrogenic activity, amplify the hypoandrogenic effect via estrogenrelated stimulation of SHBG. The hypoandrogenic effect of oral contraceptives is modulated by the progestin compound. Progestins derived from 19-nortestosterone bind androgenic receptors, whereas others exert antiandrogenic properties by antagonizing the binding of androgens to their receptors, reduce 5α-reductase, and do not bind SHBG. Through this last effect, SHBG is freely available to bind androgens, and the same progestin is totally free to exert its antiandrogenic properties. After correct evaluation of the cause of acne, appropriate management can be undertaken using oral contraceptives containing low daily doses of ethinyl estradiol (20 or 30 µg) associated with a progestin compound, such as cyproterone acetate, drospirenone, or chlormadinone acetate, the antiandrogenic activity of which has been demonstrated by many studies in animals and in humans.

show abstract

Evidence that in healthy young women, a six-cycle treatment with oral contraceptive containing 30 mcg of ethinylestradiol plus 2 mg of chlormadinone acetate reduces fat mass

Cited by 17 publications

References 23 publications

Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive

Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive

Oral Contraceptive Use does not Negatively Affect Body Composition and Strength Adaptations in Trained Women

Use of oral contraceptives in the management of acne

Contact Info

Product

Resources

About